In Patients With Metastatic Renal Cell Carcinoma Scientists Investigate Potential Markers For A Response To Sunitinib
Markers such as CA9, CD31, CD34 and VEGFR1/2 in the primary tumours might serve as predictors of a good response to a sunitinib treatment in patients with metastatic clear cell renal cell carcinoma (ccRCC), according to a new study presented at the 28th Annual EAU Congress currently on-going in Milan. "The inactivation of the von Hippel-Lindau gene (VHL) is a common event in ccRCC and finally leads to the induction of HIF1α target genes such as CA9 and VEGF," write the authors...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Cancer / Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Genetics | Health | Kidney Cancer | Politics | Renal Cell Carcinoma | Study